How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.
Pediatr Blood Cancer
; 69 Suppl 3: e29603, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35253343
ABSTRACT
Vascular anomalies (VAs) are a heterogeneous group of primarily congenital tumors and malformations. The International Society for the Study of Vascular Anomalies (ISSVA) has developed a standard classification of these disorders, creating a uniform approach to their diagnosis. Recent discoveries evaluating the genetic causes of VAs have revealed that they are due to mutations in cancer pathways, including the PI3K/AKT/mTOR and RAS/MAPK/MEK pathways. These discoveries have led to improved phenotype-genotype correlation and have expanded medical therapy for this group of unique disorders.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sirolimus
/
Vascular Malformations
Limits:
Humans
Language:
En
Journal:
Pediatr Blood Cancer
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Year:
2022
Document type:
Article
Affiliation country:
United States